Pharmacokinetics of cefazolin for prophylactic administration to dogs

by

Omar J. González-Cintrón

B.S., University of Puerto Rico, 2007
D.V.M., Tuskegee University, 2013

A Thesis

submitted in partial fulfillment of the requirements for the degree

Master of Science

Department of Clinical Sciences
College of Veterinary Medicine

Kansas State University
Manhattan, Kansas

2017

Approved by:

Major Professor
Walter Renberg, DVM, MS
Diplomate ACVS
Copyright

© OMAR J. GONZÁLEZ-CINTRÓN

2017
Abstract

OBJECTIVE: The purpose of the study reported here was to evaluate pharmacokinetics of cefazolin in dogs receiving a single IV injection of cefazolin (22 mg/kg) and dogs receiving simultaneous IV and IM injections of cefazolin (total dose, 44 mg/kg).

METHODS: Twelve purpose-bred Beagles (6/group) were assigned to receive a single injection of cefazolin (22 mg/kg, IV) or simultaneous injections (22 mg/kg, IV, and 22 mg/kg, IM). Interstitial fluid was collected over a 5-hour period using ultrafiltration probes for pharmacokinetic analysis.

RESULTS: Mean cefazolin concentration in the interstitial fluid at 1, 1.5, 2, 3, 4, and 5 hours after injection was 39.6, 29.1, 21.1, 10.3, 6.4, and 2.7 μg/mL, respectively, for the IV group and 38.3, 53.3, 46.4, 31.7, 19.1, and 8.9 μg/mL, respectively, for the IV + IM group. The mean area under the concentration-time curve extrapolated to infinity, maximum concentration, half life and time to the maximum concentration was 74.99 and 154.16 h•μg/mL, 37.3 and 51.5 μg/mL, 0.96 and 1.11 hours, 1.28 and 1.65 hours, respectively, for the IV and IV + IM groups.

CONCLUSIONS AND CLINICAL RELEVANCE: Cefazolin concentrations in interstitial fluid of dogs were maintained at > 4 μg/mL for 4 hours after a single IV injection and for 5 hours after simultaneous IV and IM injections. Based on these results, simultaneous administration of cefazolin IV + IM 30 to 60 minutes before surgery should provide interstitial fluid concentrations effective against the most common commensal organisms (Staphylococcus spp and Streptococcus spp) on the skin of dogs for surgical procedures lasting ≤ 4 hours.
# Table of Contents

LIST OF FIGURES .......................................................................................................................... v
LIST OF TABLES .............................................................................................................................. vi
LIST OF ABBREVIATIONS ............................................................................................................... vii
ACKNOWLEDGEMENTS .................................................................................................................. viii
DEDICATION .......................................................................................................................................... ix

CHAPTER 1 – USE OF ANTIMICROBIAL PROPHYLAXIS DURING SURGERY ............. 1
  Surgical Site Infections ...................................................................................................................... 1
  Antibiotic Selection ............................................................................................................................ 2
  Antibiotic Interstitial Fluid Concentration ....................................................................................... 3
  Pharmacokinetic Analysis .................................................................................................................. 4
REFERENCES ......................................................................................................................................... 6

CHAPTER 2 - PHARMACOKINETICS OF CEFAZOLIN FOR PROPHYLACTIC ADMINISTRATION TO DOGS ................................................................. 9
  Abstract ................................................................................................................................................. 10
  Introduction ............................................................................................................................................ 11
  Materials and Methods ..................................................................................................................... 14
    Animals ............................................................................................................................................... 14
    Implant placement ............................................................................................................................. 14
    Experimental design ......................................................................................................................... 15
    Sample collection ............................................................................................................................. 15
    UPLC-UV drug analysis ..................................................................................................................... 15
    Statistical analysis ............................................................................................................................ 16
  Results .................................................................................................................................................. 17
  Discussion ............................................................................................................................................ 18
  Figures ................................................................................................................................................. 23
  Tables ................................................................................................................................................... 27
  Footnotes ............................................................................................................................................. 28
REFERENCES ......................................................................................................................................... 29

Appendix A - BASi® Ultrafiltration Probe Image ............................................................................ 32
LIST OF FIGURES

Figure 1 - Semipermeable ultrafiltration probe threaded from cranial to caudal into the introducer needle to be placed subcutaneously. ................................................................. 23

Figure 2 - Mean cefazolin concentration-time curve for concentrations in interstitial fluid after administration of a single dose (22 mg/kg, IV) to 5 dogs (IV group [circles]) and simultaneous IV and IM administration (22 mg/kg, IV, and 22 mg/kg, IM) to 6 dogs (IV + IM group [squares]). Notice the MIC$_{90}$ for *Streptococcus* spp (4 μg/mL [dashed line]) and the MIC$_{90}$ for *Staphylococcus pseudintermedius* (2 μg/mL [dotted line])........................... 24

Figure 3 - Cefazolin concentration-time curves of the mean (squares), minimum (circles), and maximum (triangles) concentrations in interstitial fluid after administration of a single dose (22 mg/kg, IV) to 5 dogs (IV group [A]). Notice the MIC$_{90}$ for *Streptococcus* spp (4 μg/mL [dashed line]) and the MIC$_{90}$ for *Staphylococcus pseudintermedius* (2 μg/mL [dotted line]). .................................................................................................................. 25

Figure 4 - Cefazolin concentration-time curves of the mean (squares), minimum (circles), and maximum (triangles) concentrations in interstitial fluid after administration of a simultaneous IV and IM administration (22 mg/kg, IV, and 22 mg/kg, IM) to 6 dogs (IV + IM group [B]). Notice the MIC$_{90}$ for *Streptococcus* spp (4 μg/mL [dashed line]) and the MIC$_{90}$ for *Staphylococcus pseudintermedius* (2 μg/mL [dotted line])........................... 26

Figure A.1 UF-3-12 ultrafiltration sampling probe used in this study, with 29 μL volume capacity. .................................................................................................................................................. 32
LIST OF TABLES

Table 1 - Mean, minimum, and maximum concentrations of cefazolin (µg/kg) in interstitial fluid after administration of a single dose (22 mg/kg, IV) to 5 dogs (IV group) and simultaneous IV and IM administration (22 mg/kg, IV, and 22 mg/kg, IM) to 6 dogs (IV + IM group)...

Table 2 - Pharmacokinetics of cefazolin after administration of a single dose (22 mg/kg, IV) to 5 dogs (IV group) and simultaneous IV and IM administration (22 mg/kg, IV, and 22 mg/kg, IM) to 6 dogs (IV + IM group).
## LIST OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC</td>
<td>Area under the concentration-time curve</td>
</tr>
<tr>
<td>AUC INF</td>
<td>Area under the concentration-time curve extrapolated to infinity</td>
</tr>
<tr>
<td>HPLC</td>
<td>High performance liquid chromatography</td>
</tr>
<tr>
<td>Cmax</td>
<td>Maximum concentration in interstitial fluid</td>
</tr>
<tr>
<td>MIC</td>
<td>Minimum inhibitory concentration</td>
</tr>
<tr>
<td>MIC&lt;sub&gt;90&lt;/sub&gt;</td>
<td>Minimum inhibitory concentration at which 90% of isolates are inhibited</td>
</tr>
<tr>
<td>SSI</td>
<td>Surgical site infection</td>
</tr>
<tr>
<td>t&lt;sub&gt;1/2&lt;/sub&gt;</td>
<td>Terminal half-life</td>
</tr>
<tr>
<td>t&lt;sub&gt;max&lt;/sub&gt;</td>
<td>Time of the maximum concentration in interstitial fluid</td>
</tr>
<tr>
<td>UPLC-UV</td>
<td>Ultraperformance liquid chromatography with UV detection</td>
</tr>
</tbody>
</table>
ACKNOWLEDGEMENTS

I would like to acknowledge my masters committee Dr. Walter Renberg, Dr. James Roush and Dr. Butch Kukanich for the help and support developing this project. I would also like to acknowledge Dr. Emily Klocke and Dr. April Haynes for their mentorship and support throughout the residency program.

Finally I would like to thank Matt Warner for his laboratory assistance and Kimberly Kalosy, Nathan Kapaldo, Akaterina Davros, Stefanie Campbell, Amanda Schlagel, Qiuwen Kou and Samantha Belsan for their help on the data collection.
DEDICATION

This thesis is dedicated to my beautiful wife Xismari and my son William, without them none of this would have been possible. Thank you for believing in me and for all the support and understanding throughout this journey.
CHAPTER 1 – USE OF ANTIMICROBIAL PROPHYLAXIS

DURING SURGERY

The use of peri-operative antibiotics to decrease the incidence of surgical-site infections (SSI) has been well established.1-6 Antimicrobials are recommended in procedures associated with high risk of infection or when postoperative infection would have catastrophic consequences on the outcome of surgery.3, 7-9 In humans and animals, SSI can be a devastating complication, prolong the length of hospital stay and dramatically increase medical costs.5, 10, 11 There are some important concepts associated with the use of antimicrobial prophylaxis and they will be discussed in this report.

Surgical Site Infections

There is conflicting evidence of the efficacy of prophylactic antimicrobials in veterinary medicine, with some studies12 showing no effect and other studies showing a decrease in the incidence of SSI for routine clean surgical procedures.3, 13 A randomized blinded prospective controlled study showed that the infection rate for control dogs was significantly higher (15.7%) than the rate for dogs treated with peri-operative antimicrobials (3.8%).3 In another study, 347 of 365 dogs (95.3%) that underwent orthopedic surgery received peri-operative antibiotics. Five of 347 (0.01%) developed SSI, whereas 3 of 16 (18.7%) that did not receive peri-operative antibiotic developed SSI.13 Other studies have shown an overall infection rate between 5.9% and 8.9% for a variety of clean and clean-contaminated procedures with a conclusion that prophylaxis was not required for these procedures.14-16

Bacterial drug resistance (including multi-drug resistant bacteria), increased risk of hospital-acquired infection, and increased cost of the medical care are possible consequences of inappropriate or indiscriminate use of antimicrobials.1, 15, 17-19 A study in humans showed that antimicrobial prophylaxis was often not consistent with local or national guidelines; redosing schedule was followed at an appropriate time only in 40% of the cases but improved to 68% with an automatic reminder system.20 A different study in humans from a tertiary teaching hospital found that only 3 per cent of the procedures received an appropriate medication, dose, duration
and redose timing according to the hospital guidelines.\textsuperscript{19} Similarly, dogs undergoing orthopedic surgery showed discrepancies between standard recommendations and the antimicrobial prophylaxis used. Sixteen per cent of the dogs did not receive the drug within 60 minutes of surgery, 19\% received unnecessary repeated doses and 49\% received additional doses at an incorrect time.\textsuperscript{15}

Multiple studies have shown that the timing of antibiotic administration and redosing schedule are not always performed according to the institution guidelines. One study found that 78\% of dogs received the first antimicrobial dose before surgery; out of these dogs 84\% received the dose within 60 minutes of the first incision. Twelve percent of dogs were initially treated during surgery, 10 to 165 minutes after the first incision. If a guideline of repeated administration every 90 minutes after the first administration until closure of the surgical-site was used, 51\% dogs received the required intraoperative administration, and 19\% of dogs that did not require intraoperative dosing were treated.\textsuperscript{12} A more recent study showed a redosing incidence of 93.5\%, which they considered excellent; however, 28.4\% of dogs received antimicrobials late, with the dose being administered more than 30 minutes late in 28\% of those dogs.\textsuperscript{21}

\textbf{Antibiotic Selection}

The antibiotic selected for prophylactic use must be effective against the pathogen most likely to cause postoperative wound infection.\textsuperscript{3,7,8} Antibiotics with efficacy against commonly encountered pathogens, such as \textit{Staphylococcus spp.}, \textit{Streptococcus spp.} and sometimes \textit{Escherichia coli}, are usually recommended in veterinary medicine based on the location of the surgery. In order for antimicrobial prophylaxis to be effective, it must be present at the surgical-site at an adequate concentration before the time of contamination and throughout the surgical procedure.\textsuperscript{6-8,22,23}

Cephalosporins are effective antimicrobials, well tolerated, and obtain targeted serum and tissue concentrations.\textsuperscript{9} Cefazolin has been recommended as the ideal prophylactic antibiotic for surgery in dogs and has become one of the most common antimicrobials for peri-operative use because of its spectrum, low incidence of adverse effects, and low cost.\textsuperscript{3,7,8,24} The beta-lactam antimicrobials (penicillins and cephalosporins) are time-dependent, meaning that efficacy is correlated with the time that drug concentration remains above the minimum inhibitory
concentration (MIC) for a particular pathogen. Based on pharmacokinetic studies it has been recommended for time-dependent antimicrobials such as beta-lactams to be redosed intraoperatively every 2 half-lives in order to maintain targeted plasma concentrations.

Cefazolin is not appreciably absorbed after oral administration and must be given parenterally to achieve therapeutic serum levels. Absorbed drug is excreted unchanged by the kidneys into the urine. Elimination half-lives may be significantly prolonged in patients with severely diminished renal function. In dogs, peak levels occur in about 30 minutes after IM administration. The apparent volume of distribution at steady state is 700 mL/kg, total body clearance of 10.4 mL/min/kg with a serum elimination half-life of 48 minutes. Approximately 64% of the clearance can be attributed to renal tubular secretion. The drug is approximately 16–28% bound to plasma proteins in dogs.

**Antibiotic Interstitial Fluid Concentration**

Protein binding is a major factor in the tissue distribution of a drug. In order to predict antimicrobial activity, it is important to know the concentration of the protein-unbound antimicrobial at the site of bacterial contamination (surgical-site). A previous study has suggested that the concentration of cefazolin in the ISF is similar to plasma due to rapid equilibration of cefazolin between serum and soft tissues in the surgical wound. To date, only two studies have measured and compared the concentration of cefazolin in the surgical-site to serum by obtaining muscle biopsies and determining the antibiotic concentration by the use of a modified agar plate diffusion technique. However, tissue concentrations may underestimate true surgical site concentrations as the interstitial fluid is diluted with the intracellular fluid. One alternative to determine the antibiotic concentration in the interstitial fluid is the utilization of tissue cages and by ultrafiltration.

The concentration of antibacterial agents in the interstitial tissue fluid has been studied in an experimental model using implanted perforated Silastic capsules (tissue cages). The lining within the cage contains young fibroblasts, many capillaries, and obvious tissue spaces. The rate of diffusion into and out of the cage fluid of small molecules, such as sodium, is rapid, whereas for larger molecules, such as albumin, it is slower. These tissue cages, however, need to be
implanted 4 weeks prior to the sampling collection to allow ingrowth of cells into the cages and production of interstitial fluid.

On the other hand, some researchers have used ultrafiltration. Ultrafiltration provides a means for collecting protein-unbound cefazolin in the ISF by use of an implanted semipermeable membrane in the tissue. Previous studies have shown that an ultrafiltration device is a reliable and convenient method for collecting ISF samples from tissues in dogs. This device has become the preferred method for collecting ISF, rather than collection of tissue biopsy specimens or use of tissue cages, because of anatomic and physiologic relevance, lack of contamination from intracellular content, ease of insertion, the ability to collect serial samples with the same device, and monitoring of drug distribution in unrestrained animals. Furthermore, the ultrafiltration device provides a convenient method for continuous sample collection without residual wounds or lesions after removal of the ultrafiltration probes.

**Pharmacokinetic Analysis**

Reversed-phase gradient high performance liquid chromatography (HPLC) has become the preferred method for drug discovery and drug metabolism studies. HPLC is a technique in analytical chemistry used to separate, identify, and quantify each component in a mixture. It relies on pumps to pass a pressurized liquid solvent, containing the sample mixture, through a column filled with a solid adsorbent material. Each component in the sample interacts slightly differently with the adsorbent material, causing different flow rates for the different components and leading to the separation of the components as they flow out the column. The coupling of a mass spectrometer with liquid chromatography, and the advent of atmospheric pressure ionization interfaces, have resulted in significant improvements in sensitivity and specificity of analytical assays.

Chromatography can be described as a mass transfer process involving adsorption. HPLC relies on a column filled with adsorbent. The active component of the column, the adsorbent, is typically a granular material made of solid particles 2–50 micrometers in size. The components of the sample mixture are separated from each other due to their different degrees of interaction with the adsorbent particles. The pressurized liquid is typically a mixture of solvents and is referred to as a "mobile phase". Its composition and temperature play a major role in the
separation process by influencing the interactions taking place between sample components and adsorbent. The concentrations of cefazolin in interstitial fluid can be determined by use of ultra-performance liquid chromatography coupled with ultraviolet detection (UPLC-UV).
REFERENCES


CHAPTER 2 - PHARMACOKINETICS OF CEFAZOLIN FOR PROPHYLACTIC ADMINISTRATION TO DOGS

This portion of the thesis contains a version of a manuscript submitted for consideration for publication in the American Journal of Veterinary Research in June 2016

“Pharmacokinetics of cefazolin for prophylactic administration to dogs”

Omar J. Gonzalez DVM
Walter C. Renberg DVM, MS
James K. Roush DVM, MS
Butch KuKanich DVM, PhD
Matt Warner, MS

1Department of Clinical Sciences, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506.
2Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506.

This study was funded by an institutional grant from the Department of Clinical Sciences and by the Dean’s office of the College of Veterinary Medicine, Kansas State University
Abstract

OBJECTIVE
To evaluate pharmacokinetics of cefazolin after a single IV injection of cefazolin (22 mg/kg) and after simultaneous IV and IM injections of cefazolin (total dose, 44 mg/kg) to dogs.

ANIMALS
12 adult Beagles.

PROCEDURES
Dogs (6/group) were assigned to receive a single injection of cefazolin (22 mg/kg, IV) or simultaneous injections (22 mg/kg, IV, and 22 mg/kg, IM). Interstitial fluid was collected over a 5-hour period using ultrafiltration probes for pharmacokinetic analysis.

RESULTS
Mean cefazolin concentration in the interstitial fluid at 1, 1.5, 2, 3, 4, and 5 hours after injection was 39.6, 29.1, 21.1, 10.3, 6.4, and 2.7 μg/mL, respectively, for the IV group and 38.3, 53.3, 46.4, 31.7, 19.1, and 8.9 μg/mL, respectively, for the IV + IM group. The mean area under the concentration-time curve extrapolated to infinity, maximum concentration, half life and time to the maximum concentration was 74.99 and 154.16 h•μg/mL, 37.3 and 51.5 μg/mL, 0.96 and 1.11 hours, 1.28 and 1.65 hours, respectively, for the IV and IV + IM groups.

CONCLUSIONS AND CLINICAL RELEVANCE
Cefazolin concentrations in interstitial fluid of dogs were maintained at > 4 μg/mL for 4 hours after a single IV injection and for 5 hours after simultaneous IV and IM injections. Based on these results, simultaneous administration of cefazolin IV + IM 30 to 60 minutes before surgery should provide interstitial fluid concentrations effective against the most common commensal organisms (Staphylococcus spp and Streptococcus spp) on the skin of dogs for surgical procedures lasting ≤ 4 hours.
Introduction

It has been clearly established that perioperative administration of antimicrobials can decrease the incidence of SSIs.1-6 Antimicrobials are recommended for procedures associated with high risk of infection or when postoperative infection would have catastrophic consequences on the outcome of surgery.3,7-9 In humans and other animals, SSI can be a devastating complication, prolong the duration of hospital stay, and dramatically increase medical costs.5,10,11 There is conflicting evidence about the efficacy of prophylactic administration of antimicrobials in veterinary medicine; one investigator detected no effect,12 whereas other investigators detected a decrease in the incidence of SSI for routine clean surgical procedures.3,13 In a randomized blinded prospective controlled study,3 the infection rate for control dogs (15.7%) was significantly higher than the rate for dogs treated perioperatively with antimicrobials (3.8%). In another study,13 347 of 365 (95.3%) dogs that underwent orthopedic surgery received antimicrobials perioperatively. Only 5 of those 347 (0.01%) dogs developed SSI, whereas 3 of 16 (18.7%) dogs that did not receive antimicrobials perioperatively developed SSI. Investigators of other studies14-16 have found an overall infection rate between 5.9% and 8.9% for a variety of clean and clean-contaminated procedures, and they have concluded that prophylactic antimicrobial administration was not required for these procedures.

Antimicrobial-resistant bacteria (including multidrug resistant bacteria), increased risk of hospital-acquired infection, and increased cost of medical care are possible consequences of inappropriate or indiscriminate use of antimicrobials.1,15,17-19 Current guidelines in human medicine include use of antimicrobials only in clean-contaminated, contaminated, or dirty procedures; administration of the first dose of antimicrobial 1 hour before the first incision; readministration of the antimicrobial during surgery if the procedure is still ongoing after 2 half-lives of the drug have passed; restriction of treatment to the duration of surgery or for 24 hours, except in certain situations (i.e., gross contamination or preexisting infection); and avoiding use of newer broad-spectrum antimicrobials.12 In 1 study,20 prophylactic administration of antimicrobials to humans was often not consistent with local or national guidelines because a redosing schedule was followed at an appropriate time in only 40% of the patients, although this improved to 68% when an automatic reminder system was used. In another study19 of humans at a tertiary teaching hospital, an appropriate medication, dose, duration, and redosing schedule in
accordance with the hospital guidelines was used for only 3% of the patients. Similarly, there are discrepancies antimicrobial use and standard recommendations with regard to timing of administration before and during surgery, duration, and antimicrobial prophylaxis for dogs undergoing orthopedic surgery. In 1 study, 15% of the dogs did not receive the antimicrobial within 60 minutes after surgery, 19% received unnecessary repeated doses of the antimicrobial, and 49% received additional doses of the antimicrobial at an incorrect time.

The antimicrobial selected for prophylactic use must be effective against the pathogen or pathogens most likely to cause postoperative wound infection. Antimicrobials with efficacy against commonly encountered pathogens, such as *Staphylococcus* spp, *Streptococcus* spp, and sometimes *Escherichia coli*, are usually recommended for use in veterinary medicine on the basis of the surgery location. Cephalosporins are effective antimicrobials, are tolerated well, and achieve targeted serum and tissue concentrations. Cefazolin has been recommended as the ideal prophylactic antimicrobial for surgery in dogs and has become one of the antimicrobials most commonly used perioperatively because of its spectrum, low incidence of adverse effects, and low cost. For antimicrobial prophylaxis to be effective, an adequate concentration of the drug must be present at the surgical site before the time of contamination and throughout the surgical procedure. The β-lactam antimicrobials (penicillins and cephalosporins) are time-dependent drugs, which means that efficacy is correlated with the amount of time that drug concentration remain above the MIC for a particular pathogen. On the basis of results of pharmacokinetic studies, it has been recommended that time-dependent antimicrobials such as β-lactams should be readministered every 2 half-lives during surgery to maintain targeted plasma concentrations.

In a previous study, it was suggested that the concentration of cefazolin in the interstitial fluid is similar to the concentration in plasma owing to rapid equilibration of cefazolin between serum and soft tissues in a surgical wound. To our knowledge, the concentration of cefazolin in the surgical site has been measured and compared with serum concentrations (by obtaining muscle biopsy specimens and determining the antimicrobial concentration with a modified agar plate diffusion technique) in only 2 studies. However, tissue concentrations may underestimate true surgical site concentrations because the interstitial fluid is diluted with
intracellular fluid. An ultrafiltration probe has been used to obtain interstitial fluid in other studies.\textsuperscript{25–27} It has been found that this is a reliable, easily performed, and useful method for the evaluation of drug disposition in dogs, and it eliminates the need for collection of tissue samples or use of tissue cages to estimate concentrations in tissues.

The purpose of the study reported here was to compare the cefazolin concentration in interstitial fluid obtained from dogs receiving a single IV injection of cefazolin and dogs receiving simultaneous IV and IM injections of cefazolin. We hypothesized that the concentration in the interstitial fluid would be higher and more prolonged in the group receiving simultaneous IV and IM injections, compared with results for the group receiving only an IV injection.
Materials and Methods

Animals

Twelve purpose-bred Beagles (6 males and 6 females) were used in the study. All dogs were 1 year old and considered healthy; a physical examination, CBC, and serum biochemical profile were performed to verify health of the dogs. All dogs had an albumin concentration > 3.4 g/dL (range, 3.4 to 4.2 g/dL). All dogs were allowed to acclimatize to the environment before initiation of the study. The study was reviewed and approved by the Institutional Animal Care and Use Committee at Kansas State University.

Implant placement

Dogs were sedated with dexmedetomidine hydrochloride\textsuperscript{a} (15 µg/kg, IV). An indwelling percutaneous catheter was placed in the jugular vein, and 2 ultrafiltration probes\textsuperscript{b} were placed in the dorsum of each dog. The ultrafiltration probes contained 3 loops with a 12-cm semipermeable membrane. The semipermeable membrane in the loop consisted of pores that allowed water, electrolytes, and low-molecular-weight (< 30 KDa) molecules to diffuse across the membrane but excluded the passage of proteins, protein-bound drugs, and other high-molecular-weight compounds. For insertion of the ultrafiltration probes, an area (2.5 cm on each side of the midline at the dorsal caudolateral aspect of the scapulae) was shaved and aseptically prepared. One of the insertion sites was infused with a solution of 2% lidocaine hydrochloride\textsuperscript{c} (1 mg/kg), a stab incision was made through the skin with a No. 11 scalpel blade, and subcutaneous tissues were identified. An introducer needle was inserted in the stab incision, advanced cranially through the subcutaneous tissues for a distance of 10 cm, and exited through the skin; the ultrafiltration probe was then threaded through the needle from a cranial to caudal direction (Figure1) until the tip of the probe was flush with the tip of the introducer needle. The introducer needle containing the probe was then retracted 3 cm so that the 3 loops of the probe remained under the skin in the interstitial space and the nonpermeable portion of the probe remained external to the dog’s skin. The ultrafiltration probe was then secured to the skin with a non-absorbable nylon suture\textsuperscript{d} by use of a finger-trap pattern. A vacuum-vial needle\textsuperscript{e} was attached to the ultrafiltration probe tubing, and a collection tube was attached to that needle to apply
negative pressure on the probe system for collection of interstitial fluid through the semipermeable membrane. The probe insertion procedure then was repeated for the opposite side. After the ultrafiltration probes were inserted, sedation was reversed by administration of atipamezole hydrochloride (2.4 mg/kg, IM). The initial collection tubes were allowed to remain in place for $\geq$ 18 hours to equilibrate the system before the initiation of the study.

**Experimental design**

Dogs were assigned to 2 groups (6 dogs/group) by use of randomizing software. At 24 hours after placement of the IV catheter and filtration probes, dogs of one group (IV group) received an injection of cefazolin (22 mg/kg, IV) and dogs of the other group (IV + IM group) received simultaneous IV and IM injections of cefazolin (22 mg/kg, IV, and 22 mg/kg, IM).

**Sample collection**

Interstitial fluid was collected in a microcentrifuge tube inserted in a red top vacuum tube before (time 0) and 1, 1.5, 2, 3, 4, and 5 hours after administration of cefazolin. Samples were immediately placed on ice. All samples subsequently were stored at $-70^\circ$ C until testing was performed.

**UPLC-UV drug analysis**

Concentrations of cefazolin in interstitial fluid were determined by use of UPLC-UV at 271 nm. The mobile phase consisted of 1.7% formic acid in deionized water (solution A) and 1% formic acid in acetonitrile (solution B). The mobile phase gradient started at 90% solution A, decreased to 30% solution A from 0.1 to 2 minutes, decreased to 14.2% solution A at 2.5 minutes, and increased to 90% solution A at 2.51 minutes (total run time, 3.5 minutes). A C18 column maintained at 40°C was used for separation. The sample tray was maintained at 4°C, and injection volume was 5 μL. Interstitial fluid samples were injected directly into the UPLC-UV without prior treatment. Standard curve and quality control samples were created with pooled canine interstitial fluid (linear range, 0.25 to 250 μg/mL). Accuracy of the assay determined by use of 6 replicates each for concentrations of 0.25, 5, and 250 μg/mL was 103%, 104%, and 92% of the actual concentration, respectively. Coefficient of variation for the assay
determined by use of 6 replicates each for concentrations of 0.25, 5, and 250 µg/mL was 8%, 9%, and 6%, respectively.

**Statistical analysis**

Statistical analysis of the concentration-time curve was performed with a commercially available software package.\(^9\) Data were tested for equality of variance, and values for individual time points (1, 1.5, 2, 3, 4, and 5 hours) were compared between the 2 groups by use of an independent group means test. Pharmacokinetic analysis of interstitial fluid concentrations was performed with noncompartmental methods by use of computer software.\(^9\) Interstitial fluid pharmacokinetic parameters (AUC\(_{\text{INF}}\) [determined by use of the linear trapezoidal method] and t\(_{1/2}\)) were calculated for each dog, and descriptive statistics (geometric mean, minimum, and maximum values) were reported.\(^{28}\) Values for C\(_{\text{max}}\) and t\(_{\text{max}}\) were determined directly from the data. Statistical analysis of pharmacokinetic data was conducted with computer software\(^{9}\) by use of the Mann-Whitney rank sum test.\(^{29}\) Values were considered significant at \(P < 0.05\)
Results

The IV group initially consisted of 3 males and 3 females; however, 1 male was removed from the study because the dog removed the ultrafiltration devices before the initiation of the sample collection period. Thus, data were collected for 5 dogs in the IV group (mean body weight, 8.7 kg; range, 7.4 to 10.8 kg). The IV + IM group consisted of 3 males and 3 females (mean body weight, 9.7 kg; range, 8.7 to 10.7 kg).

Mean concentrations of cefazolin in interstitial fluid were measured for both groups (Figure 2; Table 1). Mean, minimum, and maximum concentrations of cefazolin obtained for the IV (Figure 3) and IV + IM (Figure 4) groups were plotted.

Comparing the mean cefazolin concentration in interstitial fluid between the IV and IV + IM groups revealed no significant difference at 1 hour (39.6 and 38.3 μg/mL, respectively) and 1.5 hours (29.1 and 53.3 μg/mL, respectively). However, the mean cefazolin concentration in interstitial fluid was significantly lower in the IV group, compared with the concentration in the IV + IM group, at 2 (21.1 and 46.4 μg/mL, respectively; \( P = 0.001 \)), 3 (10.3 and 31.7 μg/mL, respectively; \( P = 0.002 \)), 4 (6.4 and 19.1 μg/mL, respectively; \( P = 0.042 \)), and 5 (2.7 and 8.9 μg/mL, respectively; \( P = 0.003 \)) hours.

Comparing the mean values for pharmacokinetic parameters between the IV and IV + IM groups revealed a significant \( (P = 0.004) \) difference in AUC\(_{\text{INF}}\) (74.99 and 154.16 h•μg/mL, respectively; Table 2). In addition, the AUC\(_{\text{INF}}\) was dose related. There was no significant difference between the IV and IV + IM groups for C\(_{\text{max}}\) (37.3 and 51.5 μg/mL, respectively), t\(_{1/2}\) (0.96 and 1.11 hours, respectively), and T\(_{\text{max}}\) (1.28 and 1.65 hours, respectively).
Discussion

On the basis of results of the present study, we accepted the hypothesis that doubling the dose of cefazolin (22 mg/kg, IV, and 22 mg/kg, IM) adds 1 half-life to persistence of the drug. Although not significant, the half-life was approximately 15% (approx. 10 minutes) longer for the IV + IM group, compared with the expected half-life if the IV dose had been doubled. There is a slightly longer drug exposure with every half-life. This slight increase in exposure time may be explained by a slower absorption rate when the drug is administered IM. After achieving equilibrium between the serum and interstitial fluid as a result of the IV injection of cefazolin, and given the constant elimination rate and low protein-binding capacity of the drug, the IM injection would increase the number of unbound molecules of cefazolin available for distribution for a longer period because of the higher total dose.

In the present study, we found that concentrations of cefazolin in interstitial fluid in all dogs were maintained above 4 µg/mL for 4 hours after a single injection of cefazolin (22 mg/kg, IV) and for 5 hours after injections of cefazolin (22 mg/kg, IV, and 22 mg/kg, IM; total dose, 44 mg/kg). This concentration should provide antimicrobial activity against the most common methicillin-susceptible commensal organisms on the skin of dogs (Staphylococcus pseudintermedius and Streptococcus spp) for clean surgical procedures. On the basis of these results, cefazolin (22 mg/kg, IV, and 22 mg/kg, IM) administered 30 to 60 minutes before surgery for surgical procedures lasting ≤ 4 hours would achieve and maintain the desired interstitial fluid concentrations. Cefazolin (22 mg/kg, IV) administered 30 to 60 minutes before surgery would maintain the interstitial fluid concentrations above the MIC₉₀ for dogs undergoing short (≤ 3 hours) surgical procedures. These recommendations were based on the lowest (minimum) cefazolin concentration, rather than on the mean concentration, to maintain targeted concentrations in all dogs in the present study to reduce the risk of developing an SSI. However further studies are needed to confirm clinical extrapolation of these data. In the event that surgical time exceeds the aforementioned durations, administration of another dose of cefazolin (22 mg/kg, IV, at 4 hours after initial IV administration and 22 mg/kg, IV, at 5 hours after the initial IV and IM administration of 44 mg/kg) should maintain targeted concentrations in the interstitial fluid.
Total drug exposure (AUC\textsubscript{INF}) was approximately twice as high after 44 mg/kg (IV + IM group; 145.16 h•µg/mL), compared with the value after 22 mg/kg (IV group; 74.99 h•µg/mL), which suggested a dose-relation phenomenon. Interstitial fluid C\textsubscript{max} was less proportional (51.5 µg/mL after 44 mg/kg and 37.3 µg/kg after 22 mg/kg). The less-than-proportional C\textsubscript{max} most likely was attributable to a delay in T\textsubscript{max} caused by absorption of the IM portion of the dose. However because cephalosporins are concentration-dependent antimicrobials, the lower-than-proportional C\textsubscript{max} for the IV + IM group would not be detrimental and could be beneficial for decreasing concentration-dependent adverse effects, compared with results after IV administration of 44 mg/kg.

Protein binding is a major factor for tissue distribution of a drug.\textsuperscript{21} To predict antimicrobial activity, it is important to know the concentration of the protein-unbound antimicrobial at the site of bacterial contamination (surgical site). Ultrafiltration provides a means for collecting protein-unbound cefazolin in the interstitial fluid by implantation of a semipermeable membrane in the tissue. Investigators of other studies\textsuperscript{25–27} have found that an ultrafiltration device is a reliable and convenient method for collecting interstitial fluid samples from tissues in dogs. This device has become the preferred method for collecting interstitial fluid, rather than collecting tissue biopsy specimens or using tissue cages, because of anatomic and physiologic relevance, lack of contamination from intracellular content, ease of insertion, collection of serial samples with the same device, and monitoring drug distribution in unrestrained animals. Furthermore, the ultrafiltration device provides a convenient method for continuous sample collection without residual wounds or lesions after removal of the ultrafiltration probes.\textsuperscript{21} To our knowledge, the study reported here was the first in which an ultrafiltration probe was used to determine the cefazolin concentration in interstitial fluid. By use of this device, we were able to detect a biologically accurate concentration of cefazolin in what we anticipate will be equivalent to the tissue biophase or surgical site, rather than in serum, which is a critical factor for determining the efficacy of agents used for prophylaxis against SSIs.\textsuperscript{30}

Timing of antibiotic administration and redosing schedules are not always in accordance with institution guidelines. In 1 study,\textsuperscript{12} investigators found that 78% of dogs received the first
antimicrobial dose before surgery; however, only 84% of those dogs received the dose within 60 minutes before the first incision. Twelve percent of dogs were initially treated during surgery (10 to 165 minutes after the first incision). If a guideline of repeated administration every 90 minutes after the first administration until closure of the surgical site were used, 51% of dogs received the required intraoperative administration, and 19% of dogs that did not require intraoperative administration were treated. In a more recent study, investigators found a redosing incidence of 93.5%, which they considered excellent; however, 28.4% of dogs received antimicrobials late, with the dose being administered more than 30 minutes late in 28% of those dogs. In the study reported here, administration of cefazolin (22 mg/kg, IV, and 22 mg/kg, IM) before surgery results in antimicrobial concentrations that should be adequate against the most common skin contaminants for surgical procedures expected to last ≤ 4 hours, and a redosing schedule would not be necessary.

The bacteria most commonly involved in SSIs in dogs and cats are commensal organisms on the skin (gram-positive cocci) and normal flora from the gastrointestinal and other tracts (predominantly gram-negative rods), depending on the surgical procedure. Historically, it has been recommended that time-dependent antimicrobials such as β-lactams be readministered during surgery every 2 half-lives to maintain therapeutic concentrations during surgery. Investigators of other studies have reported that the MIC90 is 0.25 to 2 µg/mL for S. pseudintermedius, 4 µg/mL for Streptococcus spp, and 16 µg/mL for E. coli. A more recent study of E. coli revealed an MIC that inhibited 75% of isolates was 4 µg/mL and the MIC90 was 128 µg/mL. It should be considered that although isolates were collected from 33 infection sites in that study, approximately 70% of the isolates were from the urinary tract, with the ear being a distant second (7.2% of isolates), and no other body system providing more than 4% of isolates. These isolates may have been exposed to various courses of antimicrobials prior to isolation (i.e., recurrent urinary tract and otic infections) and may not be representative of bacteria that would typically be found in surgical patients.

The present study had some limitations. We were unable to determine pharmacokinetic parameters of cefazolin in serum because of presumed contamination of the percutaneous catheter with cefazolin during IV administration (data not included). Even if the drug residual in
the catheter was 0.1%, it would have biased the data substantially. Injection of the cefazolin and collection of blood samples were through the same catheter; therefore, the measured concentration of the drug in serum was not accurate, especially at early time points. Although we did not determine the pharmacokinetic parameters of cefazolin in serum, this information can be obtained from other studies.\textsuperscript{2,7,22,30} Furthermore, the primary site of interest in the present study was interstitial fluid. The AUC for serum after administration of a dose of 40 mg/kg is 192.5 h•μg/mL (11,548 μg•min/mL), and \( t_{1/2} \) is 1.26 hours (75.8 minutes).\textsuperscript{22} The AUC for serum after administration of a dose of 20 mg/kg is 135.9 h•μg/mL (8,158 μg•min/mL), and \( t_{1/2} \) is 0.91 hours (5.08 minutes).\textsuperscript{7} Investigators of another study\textsuperscript{30} found the AUC for serum after administration of a dose of 20 mg/kg is 82.5 h•μg/mL, and \( t_{1/2} \) is 1.53 hours. In the present study, AUC for the interstitial fluid was 74.99 h•μg/mL and \( t_{1/2} \) was 0.96 hours after IV administration of a dose of 22 mg/kg and AUC was 154.16 h•μg/mL and \( t_{1/2} \) was 1.11 hours after administration of a dose of 44 mg/kg (22 mg/kg, IV, and 22 mg/kg, IM). These results indicated that exposure to cefazolin after administration was extremely similar in the interstitial fluid and serum, which would indicate good penetration of the antimicrobial into a surgical site.

Purpose-bred research Beagles that were considered healthy were used in the present study. This may not have been representative of the general population because there are patient variations associated with breed and size that may alter pharmacokinetics of cefazolin. Patients with underlying conditions or metabolic diseases that may increase glomerular filtration rate may also have increased clearance of cefazolin.\textsuperscript{35}

Dogs in the present study were not anesthetized and not subjected to surgical conditions. Some operative factors, including prolonged anesthesia time, surgical procedures requiring \( > 90 \) minutes for completion, use of certain anesthetic drugs, and hypothermia, can result in a greater risk of SSI, possibly because of increased bacterial contamination, excessive tissue manipulation, and dehydration.\textsuperscript{1,15,23,26} It has been suggested\textsuperscript{35} that substantial hemorrhage necessitating volume expansion, blood transfusion, and vasopressor or inotropic administration may dilute or increase the clearance of hydrophilic compounds (including cephalosporins), which thereby decreases concentration of the drug.\textsuperscript{35}
Data for the present study supported clinical use such that a regimen of a total dose of 44 mg of cefazolin/kg (22 mg/kg, IV, and 22 mg/kg, IM) administered 30 to 60 minutes before surgical procedures expected to last $\leq 4$ hours and a single injection of cefazolin (22 mg/kg, IV) administered 30 to 60 before surgical procedures expected to last $\leq 3$ hours should provide protection against the most common contaminants on the skin of dogs and cats (S. pseudintermedius and Streptococcus spp). However, if *E coli* or other gram-negative bacteria are suspected, another antimicrobial and dosing regimen should be considered. Further studies are needed to validate these results in clinical settings and to assess interstitial fluid pharmacokinetics of cefazolin in anesthetized patients undergoing surgery.
Figure 1 - Semipermeable ultrafiltration probe threaded from cranial to caudal into the introducer needle to be placed subcutaneously.
Figure 2 - Mean cefazolin concentration-time curve for concentrations in interstitial fluid after administration of a single dose (22 mg/kg, IV) to 5 dogs (IV group [circles]) and simultaneous IV and IM administration (22 mg/kg, IV, and 22 mg/kg, IM) to 6 dogs (IV + IM group [squares]). Notice the MIC$_{90}$ for *Streptococcus* spp (4 µg/mL [dashed line]) and the MIC$_{90}$ for *Staphylococcus pseudintermedius* (2 µg/mL [dotted line]).
Figure 3 - Cefazolin concentration-time curves of the mean (squares), minimum (circles), and maximum (triangles) concentrations in interstitial fluid after administration of a single dose (22 mg/kg, IV) to 5 dogs (IV group [A]). Notice the MIC$_{90}$ for *Streptococcus* spp (4 µg/mL [dashed line]) and the MIC$_{90}$ for *Staphylococcus pseudintermedius* (2 µg/mL [dotted line]).
Figure 4 - Cefazolin concentration-time curves of the mean (squares), minimum (circles), and maximum (triangles) concentrations in interstitial fluid after administration of a simultaneous IV and IM administration (22 mg/kg, IV, and 22 mg/kg, IM) to 6 dogs (IV + IM group [B]). Notice the MIC$_{90}$ for Streptococcus spp (4 µg/mL [dashed line]) and the MIC$_{90}$ for Staphylococcus pseudintermedius (2 µg/mL [dotted line]).
Tables

**Table 1** - Mean, minimum, and maximum concentrations of cefazolin (µg/kg) in interstitial fluid after administration of a single dose (22 mg/kg, IV) to 5 dogs (IV group) and simultaneous IV and IM administration (22 mg/kg, IV, and 22 mg/kg, IM) to 6 dogs (IV + IM group).

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>IV group</th>
<th>IV + IM group</th>
<th>( P ) value*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>Minimum</td>
<td>Maximum</td>
</tr>
<tr>
<td>1</td>
<td>39.6</td>
<td>16.0</td>
<td>66.5</td>
</tr>
<tr>
<td>1.5</td>
<td>29.1</td>
<td>22.9</td>
<td>38.2</td>
</tr>
<tr>
<td>2</td>
<td>21.2</td>
<td>11.8</td>
<td>26.2</td>
</tr>
<tr>
<td>3</td>
<td>10.3</td>
<td>6.3</td>
<td>14.3</td>
</tr>
<tr>
<td>4</td>
<td>6.4</td>
<td>4.0</td>
<td>9.9</td>
</tr>
<tr>
<td>5</td>
<td>2.7</td>
<td>1.4</td>
<td>6.1</td>
</tr>
</tbody>
</table>

*Comparison of mean values between groups; results were significant at \( P < 0.05 \).

**Table 2** - Pharmacokinetics of cefazolin after administration of a single dose (22 mg/kg, IV) to 5 dogs (IV group) and simultaneous IV and IM administration (22 mg/kg, IV, and 22 mg/kg, IM) to 6 dogs (IV + IM group).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>IV group</th>
<th>IV + IM group</th>
<th>( P ) value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>( AUC_{\text{INF}} ) (h•µg/mL)</td>
<td>74.99</td>
<td>154.16</td>
<td>0.004</td>
</tr>
<tr>
<td>( C_{\text{max}} ) (µg/mL)</td>
<td>37.3</td>
<td>51.5</td>
<td>0.177</td>
</tr>
<tr>
<td>( t_{1/2} ) (h)</td>
<td>0.96</td>
<td>1.11</td>
<td>0.429</td>
</tr>
<tr>
<td>( T_{\text{max}} ) (h)</td>
<td>1.28</td>
<td>1.65</td>
<td>0.247</td>
</tr>
</tbody>
</table>

*Comparison of mean values between groups; results were significant at \( P < 0.05 \).
Footnotes

a.  Dexdomitor, Zoetis, Florham Park, NJ.
b.  Model MF-7023, BASi, West Lafayette, Ind.
c.  2% lidocaine hydrochloride, Hospira Inc, Lake Forest, Ill.
d.  Ethilon 3-0, Ethicon, Somerville, NJ

e.  Model MD-1320, BASi, West Lafayette, Ind.
f.  Antisedan, Zoetis, Florham Park, NJ.
g.  Microsoft Office Excel 2011, Microsoft Corp, Redmond, Wash.
h.  Cefazolin, Westward Pharmaceutical, Eatontown, NJ.
j.  BD, Franklin Lakes, NJ.
k.  Acquity UPLC, Waters Corp, Milford, Mass.
l.  50 X 2.1 mm, 2.7 μm pore size, Cortecs, Waters Corp, Milford Mass.
m.  WINKS SDA 6, version 6.0.93, Texasoft Inc, Cedar Hill, Tex.
n.  Phoenix 64, Certara, Princeton, NJ.
o.  Sigma Plot 12.5, Systat Software, Chicago, Ill.
REFERENCES


UF - 3-12 Ultrafiltration Probe

3 loops of membrane
each has 2cm of membrane

1cm

The 2cm membrane in each loop is folded in half, so that the length of the membrane loop is half the length of the membrane, or 1cm in this example.

Figure A.1 UF-3-12 ultrafiltration sampling probe used in this study, with 29-μL volume capacity.